
CLAIMS

1. The use of a combined selective 5-HT6/5-HT2A antagonist of formula V wherein said compound has an affinity for the 5-HT6 receptor with pKi value of greater than or equal to 8, an affinity for the 5-HT2A receptor with pKi value of greater than or equal to 8, and has a selectivity of at least 30 over the dopamine D2 receptor, the histamine H1 receptor, and the muscarinic M1 and M2 receptors for the manufacture of a medicament for treating a disease state associated with a cognitive disorder selected from the group consisting of degenerative disorders associated with learning, learning disabilities, mild cognitive impairment, age-related cognitive decline, cerebral senility, vascular dementia, AIDS-associated dementia, electric shock induced amnesia, memory impairment associated with anxiety, Down's syndrome, stroke and traumatic brain injury



Formula V;

wherein

u is from 0 to 3;

v is from 1 to 3;

Ar is optionally substituted aryl or optionally substituted heteroaryl;

each R^{16} is independently halo, alkyl, haloalkyl, cyano, $-SO_2R^f$, $-C(=O)-NR^gR^h$, $-SR^g$, $-C(=O)-R^g$, wherein each R^f, R^g and R^h and is independently hydrogen or alkyl;


R^{17} and R^{18} each independently is hydrogen or alkyl, or R^{17} and R^{18} together may form $=NR^i$ wherein R^i is hydrogen or alkyl;

R^{19} and R^{20} each independently is hydrogen or alkyl, or one of R^{19} and R^{20} is hydrogen and the other is an optionally substituted heteroaryl, or R^{19} and R^{20} together with the nitrogen to which they are attached may form an amidinyl group, a urea group, a guanidinyl group, or a five-or six-membered ring that optionally includes an additional heteroatom selected from O, N and S, or one of R^{19} and R^{20} and one of R^{17} and R^{18} together with the atoms to which they are attached may form a five- or six-membered ring that optionally includes an additional heteroatom selected from O, N and S;

and the pharmaceutically acceptable acid addition salts thereof.

~~2. The use of claim 1 wherein said compound has a further selectivity of at least 30 over the 5-HT2C receptor.~~

~~3. The use of claim 1 wherein said compound is Formula V:~~



~~Formula V;~~

~~wherein~~

~~u is from 0 to 3;~~

~~v is from 1 to 3;~~

~~Ar is optionally substituted aryl or optionally substituted heteroaryl;~~

each R^{16} is independently halo, alkyl, haloalkyl, cyano, $-SO_2R^f$, $-C(=O)-NR^gR^h$, SR^g, $-C(=O)-R^g$, wherein each R^f, R^g and R^h and is independently hydrogen or alkyl;

R^{17} and R^{18} each independently is hydrogen or alkyl, or R^{17} and R^{18} together may form $=NR^i$ wherein R^i is hydrogen or alkyl;

R^{19} and R^{20} each independently is hydrogen or alkyl, or one of R^{19} and R^{20} is hydrogen and the other is an optionally substituted heteroaryl, or R^{19} and R^{20} together with the nitrogen to which they are attached may form an amidinyl group, a urea group, a guanidinyl group, or a five or six-membered ring that optionally includes an additional heteroatom selected from O, N and S, or one of R^{19} and R^{20} and one of R^{17} and R^{18} together with the atoms to which they are attached may form a five- or six-membered ring that optionally includes an additional heteroatom selected from O, N and S;

~~and the pharmaceutically acceptable acid addition salts thereof.~~

42. The use of claim ~~31~~, wherein said compound is of Formula V, wherein u is 0, and R^{17}, R^{18}, ~~R^{21}~~R^{19}, and ~~R^{22}~~-R^{20} are hydrogen.

~~5~~3. The use of claim 42, wherein said compound is selected from the group consisting of:
(7-Phenylsulfonyl-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-(5,5-dimethyl-1,4,5,6-tetrahydro-pyrimidin-2-yl)-amine,
(6-Phenylsulfonyl-1,2,3,4-tetrahydro-naphtnalen-1-ylmethyl)-(4,5-dihydro-1H-imidazol-2-yl)-amine,
N-(6-Phenylsulfonyl-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-guanidine,
3-(6-Phenylsulfonyl-1,2,3,4-tetrahydro-naphthalen-1-yl)-propionamidine,
C-(6-Phenylsulfonyl-1,2,3,4-tetrahydro-naphthalen-1-yl)-methylamine,
(6-Phenylsulfonyl-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-methyl-amine,
N-(6-Phenylsulfonyl-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-acetamidine,
2-[6-(2-Fluoro-phenylsulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ethylamine,
and the pharmaceutically acceptable acid addition salts thereof.

(7-Phenylsulfonyl-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-(5,5-dimethyl-1,4,5,6-tetrahydro-pyrimidin-2-yl)-amine,

(6-Phenylsulfonyl-1,2,3,4-tetrahydro-naphtnalen-1-ylmethyl)-(4,5-dihydro-1H-imidazol-2-yl)-amine,

N-(6-Phenylsulfonyl-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-guanidine,

3-(6-Phenylsulfonyl-1,2,3,4-tetrahydro-naphthalen-1-yl)-propionamidine,

C-(6-Phenylsulfonyl-1,2,3,4-tetrahydro-naphthalen-1-yl)-methylamine,

(6-Phenylsulfonyl-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-methyl-amine,

N-(6-Phenylsulfonyl-1,2,3,4-tetrahydro-naphthalen-1-ylmethyl)-acetamidine,

2-[6-(2-Fluoro-phenylsulfonyl)-1,2,3,4-tetrahydro-naphthalen-1-yl]-ethylamine,

and the pharmaceutically acceptable acid addition salts thereof.